Sanofi and Regeneron Report Positive Results of Dupixent (dupilumab) in P-IIIa Dupixent Eosinophilic Esophagitis Study for EoE
Sanofi Divulges its Strategic Framework to Drive Innovation and Growth
Shots:
- The P-IIIa Dupixent Eosinophilic Esophagitis study involves assessing Dupixent (N=42) (300mg weekly) v/s PBO (N=39) in 81 patients aged 12 years and older with eosinophilic esophagitis (EoE). In addition, enrolling patients for P-IIIb for extended active treatment period to continue in 28wks
- The P-II study results: met its co-1EPs and 2EPs in DSQ baseline with reduction in disease symptoms (69% vs 32%), EoE count reduction (60% vs 5%)
- Dupixent is a mAb to inhibit the signaling of IL-4 and IL-13 proteins and has received US FDA’s Orphan Drug Designation to treat EoE in 2017
Click here to read full press release/ article | Ref: Sanofi | Image: Behance